Selvita S.A. (SLV) fair value: what the stock is really worth
We calculate from audited financials what Selvita S.A. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Selvita S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland.
Show more
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services. It also provides antibody discovery, developability, antibody characterization, antibody engineering, and other modalities. In addition, the company offers active substance, raw materials and drug products comprising scale-up and process chemistry, solid state characterization, CMC analytical support, analytical methods development and validation, nitrozoamines and other impurities, impurities identification, quality control and QP release, stability studies, formulation development, and clinical supply GMP manufacturing; extractables and leachables, and packaging and functionality; bioanalysis of small molecules; and regulatory affairs. Further, it provides method development and validation, physicochemical properties determination, five batch analysis, one batch analysis, impurities identification, certification, stability studies, process chemistry, and solid state characterization services. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Stock analysis
Selvita S.A. (SLV) currently trades at 27.50 PLN, while our model-based Fair Value estimate is 6.08 PLN, implying the stock looks roughly 352.3% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 45.87 PLN per share, and 9 of the 24 models we run sit above the 27.50 PLN price.
Bear case: the Multiples group reads lowest at 0.9700 PLN, and 15 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 4.64 PLN (bear) to 7.28 PLN (bull), the price of 27.50 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Selvita S.A. reported revenue of 364M PLN in FY2025 versus 311M PLN in FY2021, a compound +4.0%/yr. Reported net income was 813K PLN in FY2025, compounding −51.7%/yr from FY2021.
Key figures
Market cap 551M PLN (≈ $147M) · P/S ratio 1.48 · EPS (TTM) −0.2100 PLN · Net margin 0.2% · Return on equity −1.2% · Return on assets (EBIT) 5.1% · Operating margin −2.2% · Revenue (TTM) 360M PLN.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −78%, SLV screens richer than that median.
Fair Value models
Bear 4.64 PLNFair Value 6.08 PLNBull 7.28 PLN
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−44.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−44% vs −17%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 3%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score64 · Above median
Profitability
Return on assets1% · Below median
Net margin (TTM)−1% · Below median
Operating margin (TTM)−2% · Below median
Growth and dividend
Revenue growth−12% · Bottom 25%
Balance sheet
Debt / equity0.23× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B0.46× · Cheapest 25%
P/S (TTM)0.41× · Cheapest 25%
P/FCF2.2× · Cheaper than median
EV/EBITDA4.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 27
PAST (return on equity)0· sector 9
HEALTH (low debt)88· sector 96
DIVIDEND (yield)0· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Selvita S.A. Fair Value". https://www.fairvalue-calculator.com/stock/SLV
Frequently asked questions
Is Selvita S.A. (SLV) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 6.08 PLN versus a price of 27.50 PLN, about −78% upside (overvalued).
What is the fair value of SLV?
Our model-based fair value for Selvita S.A. is 6.08 PLN (as of Sep 13, 2026), built from audited fundamentals. The current price: 27.50 PLN.
What is the quality score of SLV?
Selvita S.A. has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Selvita S.A. (SLV)?
Our model-based price target is the fair value of 6.08 PLN (as of Sep 13, 2026) from 24 valuation models. Cautious scenario 4.64 PLN, optimistic scenario 7.28 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Selvita S.A. stock forecast for 2026?
Our models put fair value at 6.08 PLN, about −78% upside versus a price of 27.50 PLN (overvalued). Cautious scenario 4.64 PLN, optimistic scenario 7.28 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Selvita S.A. (SLV)?
Selvita S.A. reported trailing-twelve-month revenue of about 360M PLN (latest available figure, as of Sep 13, 2026).
What growth is priced into Selvita S.A. (SLV)?
For today's price to be fair in a discounted-cash-flow model, Selvita S.A. would have to grow free cash flow by -0.8 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.5 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of SLV use?
Our models discount Selvita S.A. at 12.1 %: a base by market capitalisation (micro), damped by beta 0.04, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Selvita S.A. that is -0.8 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Selvita S.A. (SLV) delivered so far?
Over the past 5 years revenue at Selvita S.A. grew +21.5 % a year. The price currently implies -0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Selvita S.A. (SLV) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Selvita S.A. (-0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Selvita S.A. (SLV)?
The free-cash-flow yield on the price is 13.10 %: that much free cash flow Selvita S.A. produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Selvita S.A. (SLV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Selvita S.A. it is 6.08 PLN per share (as of Sep 13, 2026), against a price of 27.50 PLN. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Selvita S.A. stock overvalued or undervalued in 2026?
As of Sep 13, 2026, SLV trades above its calculated fair value: price 27.50 PLN, fair value 6.08 PLN, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLV?
No. The price is what the market pays today (27.50 PLN); the fair value is what the company's own numbers justify (6.08 PLN). For Selvita S.A. the two are 21.42 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Selvita S.A. worth?
The market values Selvita S.A. at about 551M PLN (market capitalisation, as of Sep 13, 2026). Per share that is 27.50 PLN; our models calculate a fair value of 6.08 PLN per share.
What do the bullish and bearish scenarios say about SLV?
Our models span a range for Selvita S.A.: cautious scenario 4.64 PLN, base 6.08 PLN, optimistic 7.28 PLN per share (as of Sep 13, 2026, price 27.50 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Selvita S.A. (SLV)?
Balance-sheet figures for Selvita S.A. (as of Sep 13, 2026): return on equity −1.2%, debt of 0.23 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is SLV from its 52-week high?
Selvita S.A. trades at 27.50 PLN, about 44% below its 52-week high of 49.40 PLN and 4% above the low of 26.50 PLN (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 6.08 PLN is for.
Which stocks are comparable to Selvita S.A.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Selvita S.A. stock attractive at the current price?
The data as of Sep 13, 2026: price 27.50 PLN, calculated fair value 6.08 PLN (−78%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SLV calculated?
We run Selvita S.A. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.08 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Selvita S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Selvita S.A. right now?
The price sits above even our optimistic bull case (7.28 PLN). The favourable scenario is already priced in. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Selvita S.A.
How large is the market capitalisation of Selvita S.A. (SLV)?
The market capitalisation of Selvita S.A. is 551M PLN (≈ $147M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Selvita S.A. (SLV)?
The price-to-sales ratio of Selvita S.A. is 1.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Selvita S.A. (SLV)?
Earnings per share at Selvita S.A. are −0.2100 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Selvita S.A. (SLV)?
The net margin of Selvita S.A. is 0.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Selvita S.A. (SLV)?
The return on equity (ROE) of Selvita S.A. is −1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Selvita S.A. (SLV)?
On an EBIT basis the return on assets of Selvita S.A. is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Selvita S.A. (SLV)?
The operating margin of Selvita S.A. is −2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Selvita S.A. (SLV)?
Revenue at Selvita S.A. is growing −12.3% versus a year earlier (3y avg +0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Selvita S.A. (SLV)?
Earnings per share at Selvita S.A. are growing +92.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Selvita S.A. (SLV) carry?
The net debt of Selvita S.A. is 72.8M PLN (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Selvita S.A. in the live analysis
One click puts Selvita S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
